文献速递头颈部肿瘤放疗

HPV相关p16表达与吸烟状态对口咽癌放疗预后的影响:MARCH-HPV项目

Prognostic impact of HPV-associated p16-expression and smoking status on outcomes following radiotherapy for oropharyngeal cancer: The MARCH-HPV project.
PubMed 文献 · Radiother Oncol · 2018-01-01

该研究基于MARCH更新数据,纳入4项随机试验中815例已知p16状态和吸烟史的口咽癌患者,评估p16表达和吸烟对改变分割放疗的预后及预测作用。结果显示p16阳性患者PFS和OS显著优于阴性患者,未发现p16与分割方案的交互作用;p16阳性从不吸烟者预后最佳。

要点

  • p16阳性口咽癌患者10年PFS绝对提高28.9%,OS绝对提高32.1%。
  • 未检测到p16状态与改变分割放疗方案之间的交互作用。
  • p16阳性从不吸烟者较既往/当前吸烟者10年PFS绝对获益24.2%。

核心结论

  • p16状态对改变分割放疗无预测作用,但确认其强预后价值,p16阳性从不吸烟患者放疗后结局最优。

研究设计与样本

  • 从MARCH更新中识别4项随机试验(RTOG9003、DAHANCA6&7、RTOG0129、ARTSCAN)共815例已知p16状态和吸烟史的口咽癌患者。
  • 采用按试验分层的Cox模型,调整性别、年龄、T分期、N分期、放疗分割类型、p16和吸烟。

主要发现

  • 465例(57%)p16阳性,350例(43%)p16阴性。
  • p16阳性较阴性患者PFS显著更好(HR=0.42 [95%CI: 0.34-0.51]),10年绝对提高28.9%。
  • p16阳性较阴性患者OS显著更好(HR=0.40 [95%CI: 0.32-0.49]),10年绝对提高32.1%。
  • 未检测到p16状态与分割方案间的交互作用。
  • p16阳性亚组中,从不吸烟者PFS显著优于既往/当前吸烟者(HR=0.49 [95%CI: 0.33-0.75]),10年生存获益24.2%。

临床怎么用

  • 口咽癌放疗决策中应常规检测p16状态以进行预后分层。
  • p16阳性且从不吸烟患者可预期更优放疗结局,吸烟状态应纳入预后评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Evaluate the prognostic and predictive impact of HPV-associated p16-expression and assess the combined prognostic impact of p16 and smoking on altered fractionated radiotherapy (AFRT) for oropharyngeal cancer (OPC) within the frames of the update of the Meta-Analysis of Radiotherapy in Carcinomas of Head and neck (MARCH). MATERIALS AND METHODS: Patients with OPC, known tumor p16-status and smoking history were identified from the MARCH update, resulting in a dataset of 815 patients from four randomized trials (RTOG9003, DAHANCA6&7, RTOG0129, ARTSCAN). Analysis was performed using a Cox model stratified by trial and adjusted on gender, age, T-stage, N-stage, type of radiotherapy fractionation, p16, smoking. Primary endpoint was progression-free survival (PFS). RESULTS: In total, 465 patients (57%) had p16-positive tumors and 350 (43%) p16-negative. Compared to p16-negative, p16-positive patients had significantly better PFS (HR = 0.42 [95% CI: 0.34-0.51], 28.9% absolute increase at 10 years) and OS (HR = 0.40 [0.32-0.49], 32.1% absolute increase at 10 years). No interaction between p16-status and fractionation schedule was detected. Smoking negatively impacted outcome; in the p16-positive subgroup, never smokers had significantly better PFS than former/current smokers (HR = 0.49 [0.33-0.75], 24.2% survival benefit at 10 years). CONCLUSIONS: No predictive impact of p16-status on response to AFRT could be detected but the strong prognostic impact of p16-status was confirmed and especially p16-positive never smoking patients have superior outcome after RT.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Lassen P, Lacas B, Pignon JP, et al. Prognostic impact of HPV-associated p16-expression and smoking status on outcomes following radiotherapy for oropharyngeal cancer: The MARCH-HPV project. Radiother Oncol. 2018. PMID: 29100700. doi:10.1016/j.radonc.2017.10.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。